GO:0046330 positive regulation of JNK cascade: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046330 describes any process that activates or increases the frequency, rate or extent of signal transduction mediated by the JNK cascade.
• The JNK cascade is a mitogen-activated protein kinase (MAPK) pathway that responds to stress, cytokines, and growth signals, and its positive regulation controls cell fate decisions including survival, apoptosis, and necroptosis.
• Key upstream regulators include MAP3Ks such as ASK1, MLK, and TAK1, which phosphorylate and activate MKK4/MKK7, the direct activators of JNK.
• Dysregulated positive regulation of JNK cascade contributes to cerebral ischemia/reperfusion injury, cancer progression, and neuropsychiatric disorders.
• Experimental models for studying GO:0046330 include knockout, point-mutation, knock-in, and overexpression cell lines, as well as CRISPR library screening.
• The term is distinct from JNK cascade itself (GO:0007254) and from negative regulation of JNK cascade (GO:0046329), focusing specifically on activating inputs.
Description
The c-Jun N-terminal kinase (JNK) cascade is a central stress-activated MAPK signaling module that converts extracellular and intracellular cues into phosphorylation-dependent changes in gene expression, cytoskeletal dynamics, and cell survival. The Gene Ontology term GO:0046330, positive regulation of JNK cascade, captures all molecular events that activate or enhance this cascade, from receptor-proximal signaling to scaffold-mediated amplification. Understanding this term is essential because excessive or mislocalized JNK activation is a hallmark of ischemic injury, neurodegeneration, and multiple cancers, making it a prime target for therapeutic intervention. Researchers rely on GO:0046330 to annotate genes that promote JNK signaling, to interpret transcriptomic and proteomic data, and to design CRISPR-based experiments that test causality. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of the mechanisms, key genes, disease links, and experimental methods associated with positive regulation of JNK cascade.
positive regulation of JNK cascade At A Glance
| GO ID | GO:0046330 |
|---|---|
| GO term | positive regulation of JNK cascade |
| Ontology | biological_process |
| Synonym | activation of JNK cascade; stimulation of JNK cascade; up regulation of JNK cascade; up-regulation of JNK cascade; upregulation of JNK cascade |
| Major function | Activates or increases the frequency, rate or extent of signal transduction mediated by the JNK cascade |
| Parent terms | positive regulation of stress-activated MAPK cascade; positive regulation of MAPK cascade |
| Related terms | JNK cascade (GO:0007254); negative regulation of JNK cascade (GO:0046329) |
| Cellular context | Cytoplasm, nucleus, and scaffold-associated signaling complexes |
| Key upstream kinases | MAP3Ks (e.g., ASK1, MLK, TAK1) and MKK4/MKK7 |
| Key downstream effectors | JNK1/2/3 and c-Jun, ATF2, ELK1 |
What Is GO:0046330?
GO:0046330, positive regulation of JNK cascade, is defined by QuickGO as any process that activates or increases the frequency, rate or extent of signal transduction mediated by the JNK cascade. In practice, this includes the action of upstream kinases, scaffold proteins, adaptors, and phosphatases that enhance JNK phosphorylation and downstream effector activation. The term is a biological process and is a child of positive regulation of stress-activated MAPK cascade and positive regulation of MAPK cascade. Synonyms include activation of JNK cascade, stimulation of JNK cascade, up regulation of JNK cascade, up-regulation of JNK cascade, and upregulation of JNK cascade. It is distinct from the JNK cascade itself (GO:0007254) and from negative regulation of JNK cascade (GO:0046329).
Why Is positive regulation of JNK cascade Important in Cell Biology?
Positive regulation of JNK cascade is critically important because it determines whether cells survive, die, or undergo necroptosis in response to stress, cytokines, and oncogenic signals. In cerebral ischemia/reperfusion injury, enhanced JNK activation promotes necroptosis through RIPK3/AIF signaling, and inhibiting this positive regulation is neuroprotective. In cancer, aberrant activation of the JNK cascade downstream of oncogenic tyrosine phosphatases or RTEL1 drives tumorigenesis and poor progression. In neuropsychiatric research, antipsychotic drugs such as clozapine modulate MAPK signaling, including JNK, highlighting the pathway's role in neuronal function. Thus, GO:0046330 provides a mechanistic framework for understanding and manipulating these diverse biological outcomes.
• Mediates stress-induced apoptosis and necroptosis in ischemia/reperfusion injury.
• Contributes to tumorigenesis and cancer progression through JNK/ELK1 and related cascades.
• Is a downstream target of oncogenic tyrosine phosphatases, offering therapeutic opportunities.
• Modulates hedgehog signaling in gastric cancer, linking JNK to developmental pathways.
• Influences neurotrophin-dependent survival/death decisions in neurons.
• Regulates tau expression via Ras signaling, connecting JNK to neurodegeneration.
• Plays a role in Hodgkin's lymphoma cell fate through cell surface receptors.
• Is modulated by antipsychotic drugs such as clozapine, relevant to schizophrenia treatment.
• Serves as a biomarker and therapeutic target in inflammatory and metabolic diseases.
• Enables CRISPR-based functional genomics to identify novel regulators of JNK signaling.
What Happens During positive regulation of JNK cascade?
Upstream activation of MAP3Ks
In simple terms: First, stress or cytokine signals turn on a group of kinases called MAP3Ks.
Positive regulation of the JNK cascade begins with the activation of MAP3Ks such as ASK1, MLK, and TAK1 in response to stress, cytokines, or growth factors. These kinases are often recruited to scaffold complexes that bring them into proximity with downstream MKKs. In cerebral ischemia/reperfusion, ASK1 activation is a key step that promotes JNK phosphorylation and subsequent necroptosis. Similarly, in gastric cancer, MAP3K-dependent activation of the JNK cascade modulates hedgehog signaling.
Phosphorylation of MKK4/MKK7
In simple terms: The MAP3Ks then activate MKK4 and MKK7, which are the direct switches for JNK.
Activated MAP3Ks phosphorylate and activate the dual-specificity kinases MKK4 and MKK7. These kinases serve as the immediate upstream activators of JNK, and their phosphorylation is a hallmark of positive regulation of the JNK cascade. MKK7 preferentially phosphorylates threonine and tyrosine residues within the TPY motif of JNK, leading to JNK activation. This step is tightly controlled by scaffold proteins and phosphatases that can either enhance or dampen the signal.
JNK activation and substrate phosphorylation
In simple terms: Active JNK then phosphorylates many proteins that change cell behavior.
Once activated, JNK phosphorylates serine/threonine residues on substrates such as c-Jun, ATF2, and ELK1, leading to changes in transcription factor activity. In gliomas, RTEL1 promotes tumorigenesis through the JNK/ELK1 cascade, demonstrating how positive regulation of JNK cascade can drive oncogenic gene expression. JNK also phosphorylates non-nuclear substrates that regulate cytoskeletal dynamics and cell survival.
Scaffold and adaptor protein modulation
In simple terms: Scaffold proteins hold the components together and make the signal stronger or weaker.
Scaffold proteins such as JIP1, JIP2, and POSH positively regulate the JNK cascade by assembling MAP3K-MKK-JNK modules and facilitating their activation. Adaptor proteins like TRAF2 and TRAF6 also contribute to JNK activation downstream of TNF receptors and other immune receptors. These scaffolds ensure signaling specificity and can be targeted to modulate the cascade in disease contexts.
Crosstalk with other signaling pathways
In simple terms: The JNK cascade talks to other pathways, so its positive regulation is influenced by many signals.
Positive regulation of the JNK cascade is influenced by crosstalk with the Ras, hedgehog, and neurotrophin signaling pathways. For example, Ras signaling positively regulates tau expression in PC12 cells, and this effect may involve JNK cascade components. Neurotrophins can either promote survival or death through JNK-dependent mechanisms, depending on cellular context. Such crosstalk expands the range of inputs that can positively regulate the JNK cascade.
Key Genes Involved in GO:0046330 positive regulation of JNK cascade
The following genes and proteins are central to the positive regulation of the JNK cascade, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MAP3K5 (ASK1) | MAP3K that activates MKK4/MKK7 in response to stress | Key mediator of ischemia/reperfusion injury and necroptosis |
| MAP2K4 (MKK4) | Dual-specificity kinase that phosphorylates JNK | Direct activator of JNK; target for pathway inhibition |
| MAP2K7 (MKK7) | Dual-specificity kinase that phosphorylates JNK | Essential for JNK activation in stress responses |
| MAPK8 (JNK1) | Effector kinase that phosphorylates c-Jun and other substrates | Central to stress-induced apoptosis and survival |
| MAPK9 (JNK2) | Effector kinase with overlapping and distinct functions | Modulates cell fate in cancer and neuropsychiatric disorders |
| MAPK10 (JNK3) | Neuron-specific JNK isoform | Implicated in neurodegeneration and neurotrophin signaling |
| JUN (c-Jun) | Transcription factor phosphorylated by JNK | Drives AP-1-dependent gene expression in cancer |
| ATF2 | Transcription factor activated by JNK | Mediates stress-responsive gene expression |
| ELK1 | Transcription factor phosphorylated by JNK | Promotes tumorigenesis in gliomas via JNK/ELK1 |
| RTEL1 | DNA helicase that can activate JNK/ELK1 cascade | High expression predicts worse glioma progression |
| RIPK3 | Kinase involved in necroptosis downstream of JNK | Mediates ischemic injury through RIPK3/AIF axis |
| AIF (AIFM1) | Apoptosis-inducing factor in necroptosis | Effector of JNK-dependent necroptosis |
| TRAF2 | Adaptor protein that promotes JNK activation | Links TNF receptor signaling to JNK cascade |
| TRAF6 | Adaptor protein that promotes JNK activation | Mediates immune receptor signaling to JNK |
| MAP3K1 (MEKK1) | MAP3K that activates JNK pathway | Regulates hedgehog signaling in gastric cancer |
| MAP3K7 (TAK1) | MAP3K that activates JNK in inflammatory signaling | Links cytokine receptors to JNK activation |
| DUSP1 (MKP-1) | Phosphatase that negatively regulates JNK | Modulates the threshold of positive regulation |
| PTPN11 (SHP2) | Tyrosine phosphatase that can modulate JNK | Oncogenic phosphatase affecting MAPK signaling |
How Is positive regulation of JNK cascade Regulated?
Positive regulation of the JNK cascade is itself tightly regulated by multiple mechanisms. Scaffold proteins such as JIP1 and POSH enhance JNK activation by assembling kinase modules, while phosphatases like DUSP1 (MKP-1) dephosphorylate JNK and terminate the signal. Upstream of MAP3Ks, small GTPases of the Rho family and adaptor proteins like TRAF2/6 transmit receptor signals to the cascade. In cancer, oncogenic tyrosine phosphatases such as SHP2 can modulate JNK activity, contributing to tumorigenesis. Additionally, crosstalk with the hedgehog and neurotrophin pathways can either amplify or attenuate JNK signaling depending on context. This multilayered regulation ensures that JNK activation is transient and appropriate to the stimulus.
positive regulation of JNK cascade and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MAP3K5 (ASK1) | Cerebral ischemia/reperfusion injury | Knockout rat or mouse model of middle cerebral artery occlusion |
| RTEL1 | Glioma progression | Overexpression and knockout glioma cell lines |
| PTPN11 (SHP2) | Oncogenic tyrosine phosphatase-driven cancers | Point-mutation knock-in cell lines |
| MAP3K1 (MEKK1) | Gastric cancer and hedgehog signaling | Knockout gastric cancer cell lines |
| TRAF2/TRAF6 | Hodgkin's lymphoma | Knockout lymphoma cell lines |
Cerebral Ischemia/Reperfusion Injury
Positive regulation of the JNK cascade plays a detrimental role in cerebral ischemia/reperfusion injury by promoting necroptosis through the RIPK3/AIF pathway. In rat models, JNK activation correlates with neuronal death, and inhibiting JNK signaling reduces infarct size and improves neurological outcomes. This makes components of the JNK cascade attractive therapeutic targets for stroke and related ischemic conditions.
Cancer Progression
Aberrant positive regulation of the JNK cascade contributes to tumorigenesis in multiple cancers. In gliomas, high expression of RTEL1 activates the JNK/ELK1 cascade, promoting tumor growth and predicting worse progression. Oncogenic tyrosine phosphatases can also enhance JNK signaling, supporting cancer cell survival and proliferation. In gastric cancer, MAPK cascade regulation of hedgehog signaling highlights the interplay between JNK and developmental pathways.
Neuropsychiatric and Neurodegenerative Disorders
Modulation of JNK signaling is implicated in antipsychotic drug action; clozapine affects MAPK signal transduction, including JNK, suggesting a role in schizophrenia treatment. Neurotrophins influence neuronal survival/death decisions through JNK-dependent mechanisms, linking positive regulation of JNK cascade to neurodegeneration. Additionally, Ras signaling positively regulates tau expression in PC12 cells, connecting JNK to tauopathies.
Lymphoma and Immune Signaling
In Hodgkin's lymphoma, cell surface receptors regulate tumor cell fate through pathways that include JNK activation. Adaptor proteins such as TRAF2 and TRAF6 transmit signals from these receptors to the JNK cascade, influencing proliferation and survival. Targeting positive regulation of JNK cascade may therefore offer therapeutic benefits in lymphoid malignancies.
From positive regulation of JNK cascade-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of MAP3K5 reduce JNK activation and necroptosis after ischemia? | MAP3K5 knockout rat or mouse |
| Does RTEL1 overexpression enhance JNK/ELK1-driven tumorigenesis? | RTEL1 overexpression and knockout glioma cells |
| Does a point mutation in PTPN11 alter JNK cascade activity? | PTPN11 point-mutation knock-in cell lines |
| Does MKK7 knock-in of a phospho-mimetic mutant sustain JNK activation? | MKK7 knock-in cell lines |
| Can CRISPR library screening identify novel positive regulators of JNK cascade? | Genome-wide CRISPR knockout library in reporter cells |
| Does tagged JNK1 knock-in reveal real-time signaling dynamics? | Tagged JNK1 knock-in cell lines |
How to Study the positive regulation of JNK cascade Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blotting | Phosphorylation of JNK, c-Jun, ATF2 | Validation of pathway activation in cell models |
| Phospho-proteomics | Global phosphorylation changes | Discovery of novel JNK substrates and regulators |
| RNA-seq | Transcriptional changes downstream of JNK | Identification of JNK-dependent gene signatures |
| CRISPR knockout screen | Genes required for JNK activation | Functional genomics of positive regulation |
| CRISPR activation screen | Genes that enhance JNK signaling | Discovery of positive regulators |
| Luciferase reporter assay | JNK-responsive transcription | High-throughput chemical or genetic screens |
| Live-cell imaging | Real-time JNK activation dynamics | Spatiotemporal analysis of signaling |
| Co-immunoprecipitation | Protein-protein interactions in JNK complexes | Mapping scaffold and adaptor networks |
Phospho-Proteomics and Western Blotting
Phospho-specific antibodies against JNK, c-Jun, and ATF2 are used to measure activation status of the JNK cascade. Western blotting provides semi-quantitative assessment, while phospho-proteomics can identify novel substrates and crosstalk nodes. These methods are essential for validating positive regulation in knockout or overexpression models.
Transcriptomics and RNA-seq
RNA-seq can reveal downstream transcriptional changes driven by JNK activation, such as AP-1 target genes. Comparing wild-type and knockout cells identifies genes whose expression depends on positive regulation of JNK cascade. This approach is useful for discovering biomarkers and therapeutic targets.
CRISPR Library Screening
Genome-wide CRISPR knockout or activation screens can identify genes that positively regulate the JNK cascade. Reporter cell lines expressing JNK-responsive fluorescent or luminescent reporters enable high-throughput screening. Hits from these screens can be validated individually using targeted knockouts or overexpression.
Imaging and Reporter Assays
Live-cell imaging with fluorescently tagged JNK or downstream effectors allows real-time monitoring of cascade activation. Luciferase reporters driven by AP-1 or JNK-responsive promoters provide quantitative readouts for chemical or genetic perturbations. These methods are particularly useful for studying spatial and temporal dynamics of positive regulation.
How CRISPR Can Be Used to Study GO:0046330 positive regulation of JNK cascade
Knockout
CRISPR knockout of positive regulators such as MAP3K5, MAP2K4, or MAP2K7 can abolish JNK activation and provide causal evidence for their role in the cascade. Knockout cell lines are also used to validate hits from CRISPR screens and to test disease-related phenotypes, such as reduced necroptosis after ischemia.
Point Mutation
Point mutations can be introduced to mimic or prevent phosphorylation of key residues in JNK cascade components. For example, phospho-mimetic or phospho-deficient mutants of MKK7 or JNK can reveal the importance of specific phosphorylation events in positive regulation. Such models are valuable for dissecting molecular mechanisms.
Knock-in
Knock-in of tagged versions of JNK or its regulators (e.g., GFP-JNK1) allows real-time imaging and biochemical isolation of signaling complexes. Knock-in of disease-associated mutations, such as those in PTPN11, can model how these mutations affect JNK cascade activity.
Overexpression
Overexpression of candidate positive regulators, such as RTEL1 or constitutively active MAP3Ks, can enhance JNK activation and drive downstream phenotypes like tumorigenesis. Overexpression models are useful for gain-of-function studies and for testing therapeutic inhibitors.
How EDITGENE Supports positive regulation of JNK cascade Research
Researchers studying positive regulation of JNK cascade-related genes often need to determine whether a candidate gene is causally involved in activating or enhancing the cascade. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from gene knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of JNK cascade research.
Frequently Asked Questions About positive regulation of JNK cascade
What is GO:0046330?
GO:0046330 is the Gene Ontology term for positive regulation of JNK cascade, defined as any process that activates or increases the frequency, rate or extent of signal transduction mediated by the JNK cascade.
What genes are involved in positive regulation of JNK cascade?
Key genes include MAP3K5 (ASK1), MAP2K4 (MKK4), MAP2K7 (MKK7), MAPK8 (JNK1), MAPK9 (JNK2), MAPK10 (JNK3), JUN, ATF2, ELK1, and RTEL1, among others.
How is the JNK cascade activated?
The JNK cascade is activated when upstream MAP3Ks phosphorylate MKK4/MKK7, which in turn phosphorylate JNK, leading to activation of transcription factors like c-Jun.
What diseases are associated with positive regulation of JNK cascade?
It is associated with cerebral ischemia/reperfusion injury, cancer progression, neuropsychiatric disorders, and lymphoma.
What is the difference between JNK cascade and positive regulation of JNK cascade?
JNK cascade (GO:0007254) refers to the signaling pathway itself, while positive regulation of JNK cascade (GO:0046330) specifically describes processes that activate or enhance that pathway.
How can I study positive regulation of JNK cascade in the lab?
Common methods include Western blotting for phospho-JNK, CRISPR knockout screens, RNA-seq, and luciferase reporter assays.
What are the synonyms for GO:0046330?
Synonyms include activation of JNK cascade, stimulation of JNK cascade, up regulation of JNK cascade, up-regulation of JNK cascade, and upregulation of JNK cascade.
Which CRISPR model is best for studying JNK cascade regulators?
Knockout models are ideal for loss-of-function studies, while overexpression and knock-in models are suited for gain-of-function and dynamic studies.
Can EDITGENE help with CRISPR screening for JNK cascade regulators?
Yes, EDITGENE offers genome-wide CRISPR knockout and activation screens coupled with JNK-responsive reporters to identify novel regulators.
What is the role of RTEL1 in JNK cascade?
RTEL1 can activate the JNK/ELK1 cascade, promoting tumorigenesis in gliomas and predicting worse progression.
Conclusion
GO:0046330, positive regulation of JNK cascade, is a fundamental biological process that governs cellular responses to stress, cytokines, and oncogenic signals. Its dysregulation contributes to a wide range of diseases, including ischemic injury, cancer, and neuropsychiatric disorders. Understanding the molecular mechanisms and key regulators of this process is essential for developing targeted therapies. EDITGENE provides comprehensive CRISPR-based tools to investigate positive regulation of JNK cascade, from knockout and point-mutation models to library screening and bioinformatics support.
References
- 1. Hu W et al.. 2020. Regulation of JNK signaling pathway and RIPK3/AIF in necroptosis-mediated global cerebral ischemia/reperfusion injury in rats.. Exp Neurol 331:113374 PMID: 32502579
- 2. Browning JL et al.. 2005. Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions.. Biol Psychiatry 57(6):617-23 PMID: 15780848
- 3. Wang G et al.. 2024. High expression of RTEL1 predicates worse progression in gliomas and promotes tumorigenesis through JNK/ELK1 cascade.. BMC Cancer 24(1):385 PMID: 38532312
- 4. Frankson R et al.. 2017. Therapeutic Targeting of Oncogenic Tyrosine Phosphatases.. Cancer Res 77(21):5701-5705 PMID: 28855209
- 5. Seto M et al.. 2009. Regulation of the hedgehog signaling by the mitogen-activated protein kinase cascade in gastric cancer.. Mol Carcinog 48(8):703-12 PMID: 19142899
- 6. Casaccia-Bonnefil P et al.. 1999. Neurotrophins in cell survival/death decisions.. Adv Exp Med Biol 468:275-82 PMID: 10635036
- 7. Sadot E et al.. 1998. Ras-signaling pathways: positive and negative regulation of tau expression in PC12 cells.. J Neurochem 70(1):428-31 PMID: 9422391
- 8. Yurchenko M et al.. 2010. Hodgkin's lymphoma: the role of cell surface receptors in regulation of tumor cell fate.. Exp Oncol 32(4):214-23 PMID: 21270747
